The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Drugs Used to Treat Osteoporosis: The Critical Need for a Uniform Nomenclature Based on Their Action on Bone Remodeling
Abstract
There continues to be uncertainty about the classification of available drugs for treating osteoporosis. We find that grouping them into anti-catabolic and anabolic classes based on the mechanisms of their action on bone remodeling and fracture reduction removes ambiguities and provides a relatively straightforward classification. The recent introduction of teriparatide into clinical practice initiated the era of anabolic therapy for osteoporosis, but it is still unclear how to define an anabolic drug. All drugs that increase bone mass do so by affecting bone remodeling. When their mechanisms of action on bone remodeling and on fracture reduction are considered, we find that anti-osteoporotic drugs fall naturally into either anti-catabolic or anabolic classes. Anti-catabolic drugs increase bone strength and reduce fractures mainly by decreasing the number of bone multicellular units (BMUs). This reduces perforative resorption and preserves skeletal microarchitecture (by preventing further structural damage to trabecular bone and increased porosity in cortical bone induced by high bone remodeling). Reduction in bone remodeling by anti-catabolic drugs may increase bone mass moderately during the interval in which previously initiated BMUs are completing mineralization. Some anti-catabolic drugs may also enhance the formation phase of the remodeling cycle, but their major action is to reduce overall bone turnover (i.e., the number of BMUs in bone). In contrast, anabolic drugs increase bone strength and reduce fractures by substantially increasing bone mass as a result of an overall increase in the number of BMUs combined with a positive BMU balance (the magnitude of the formation phase is greater than that of the resorption phase). Some anabolic drugs also induce renewed modeling, increase periosteal apposition and repair of trabecular microstructure. We hope that this classification will serve as a starting point for continued discussion on the important issue of nomenclature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Manolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,568
Riggs, B. L., & Melton, L. J. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606263142605 · Cited by 1,915
Self-citationMeunier, P. J., Roux, C., Seeman, E., Ortolani, S., Badurski, J. E., Spector, T. D., Cannata, J., Balogh, A., Lemmel, E.-M., Pors-Nielsen, S., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa022436 · Cited by 1,638
Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., Ravoux, A.-C., Shah, A. S., Huster, W. J., Draper, M., & Christiansen, C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712043372301 · Cited by 1,637
Parfitt, A. M., Mathews, C. H., Villanueva, A. R., Kleerekoper, M., Frame, B., & Rao, D. S. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111096 · Cited by 1,545
Self-citationChesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122 · cited 5×
“Thus, the only currently available drug that is clearly anabolic is teriparatide [PTH(1-34)] by daily injection, although a similar regimen using full-length parathyroid hormone [PTH(134)] may soon become clinically available.”
BackgroundInfluentialEffect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women with Osteoporosis
Riggs, B. L., Hodgson, S. F., O'Fallon, W. M., Chao, E. Y. S., Wahner, H. W., Muhs, J. M., Cedel, S. L., & Melon, L. J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199003223221203 · Cited by 1,088
Self-citationIncreased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., & Manolagas, S. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6610 · Cited by 1,043
Self-citation
Cited by
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
Estrogen deficiency and bone loss: an inflammatory tale
Weitzmann, M. N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28550 · Cited by 990
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH
Jilka, R. L. (2007) · Bone · doi:10.1016/j.bone.2007.03.017 · Cited by 720
Khosla, S., Riggs, B. L., Atkinson, E. J., Oberg, A. L., McDaniel, L. J., Holets, M., Peterson, J. M., & Melton, L. J. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050916 · Cited by 583
Self-citationIs insulin an anabolic agent in bone? Dissecting the diabetic bone for clues
Thrailkill, K. M., Lumpkin, C. K., Bunn, R. C., Kemp, S. F., & Fowlkes, J. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00159.2005 · Cited by 490
Long-term clinical study and multiscale analysis of in vivo biodegradation mechanism of Mg alloy
Lee, J.-W., Han, H.-S., Han, K.-J., Park, J., Jeon, H., Ok, M.-R., Seok, H.-K., Ahn, J.-P., Lee, K. E., Lee, D.-H., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518238113 · Cited by 480
Regulation of C-Terminal and Intact FGF-23 by Dietary Phosphate in Men and Women
Burnett, S.-A. M., Gunawardene, S. C., Bringhurst, F. R., Jüppner, H., Lee, H., & Finkelstein, J. S. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060507 · Cited by 455
MacNeil, J. A., & Boyd, S. K. (2008) · Bone · doi:10.1016/j.bone.2008.01.017 · Cited by 440
The role of the immune system in the pathophysiology of osteoporosis
Clowes, J. A., Riggs, B. L., & Khosla, S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00334.x · Cited by 359
Self-citationBone Remodeling in Post-menopausal Osteoporosis
Lerner, U. H. (2006) · Journal of Dental Research · doi:10.1177/154405910608500703 · Cited by 347
Strontium signaling: Molecular mechanisms and therapeutic implications in osteoporosis
Saidak, Z., & Marie, P. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.009 · Cited by 334
Hip Fractures and the Contribution of Cortical Versus Trabecular Bone to Femoral Neck Strength
Holzer, G., von Skrbensky, G., Holzer, L. A., & Pichl, W. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081108 · Cited by 319
Age-Related Changes in Trabecular and Cortical Bone Microstructure
Chen, H., Zhou, X., Fujita, H., Onozuka, M., & Kubo, K.-Y. (2013) · International Journal of Endocrinology · doi:10.1155/2013/213234 · Cited by 305
Model structure and control of bone remodeling: A theoretical study
Pivonka, P., Zimak, J., Smith, D. W., Gardiner, B. S., Dunstan, C. R., Sims, N. A., John Martin, T., & Mundy, G. R. (2008) · Bone · doi:10.1016/j.bone.2008.03.025 · Cited by 298
Fracture healing in the elderly patient
Gruber, R., Koch, H., Doll, B. A., Tegtmeier, F., Einhorn, T. A., & Hollinger, J. O. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.09.008 · Cited by 283
Osteoporosis: An Age-Related and Gender-Specific Disease – A Mini-Review
Pietschmann, P., Rauner, M., Sipos, W., & Kerschan-Schindl, K. (2009) · Gerontology · doi:10.1159/000166209 · Cited by 262
Osteoblasts in osteoporosis: Past, emerging, and future anabolic targets
Marie, P. J., & Kassem, M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0132 · Cited by 234
Re-thinking the bone remodeling cycle mechanism and the origin of bone loss
Delaisse, J.-M., Andersen, T. L., Kristensen, H. B., Jensen, P. R., Andreasen, C. M., & Søe, K. (2020) · Bone · doi:10.1016/j.bone.2020.115628 · Cited by 152
Estrogen deficiency, T cells and bone loss
Pacifici, R. (2008) · Cellular Immunology · doi:10.1016/j.cellimm.2007.06.008 · Cited by 146
Transforming Growth Factor-β1 (TGF-β1) Induces Human Osteoclast Apoptosis by Up-regulating Bim
Houde, N., Chamoux, E., Bisson, M., & Roux, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.019372 · Cited by 80
Sphingosine 1-phosphate signaling in bone remodeling: multifaceted roles and therapeutic potential
Meshcheryakova, A., Mechtcheriakova, D., & Pietschmann, P. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1332180 · Cited by 74
Adaptation of the Skeletal System During Long-Duration Spaceflight
Sibonga, J. D., Cavanagh, P. R., Lang, T. F., LeBlanc, A. D., Schneider, V. S., Shackelford, L. C., Smith, S. M., & Vico, L. (2007) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-008-9012-8 · Cited by 67
“With 1-2 million bone remodeling units in the adult skeleton [7], a negative balance of bone in each unit can reduce skeletal mass over time and compromise the skeleton’s integrity under normal mechanical loading.”
BackgroundEstrogen Deficiency, Postmenopausal Osteoporosis, and Age-Related Bone Loss
Khosla, S., & Pacifici, R. (2013) · Osteoporosis · doi:10.1016/b978-0-12-415853-5.00046-7 · Cited by 31
Javaid, M. K., & Holt, R. I. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107087955 · Cited by 28
“Agents that are used in the prevention and treatment of osteoporosis are generally classified as either anti-catabolic or anabolic (Riggs and Parfitt, 2005).”
Background
Metadata
- Authors
- Riggs, B. L., & Parfitt, A. M.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-02-01
- Volume
- 20
- Issue
- 2
- Pages
- 177-184
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2092721372
- Cited by
- 380
- References
- 54
- FWCI
- 35.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.